GIANNATEMPO, PATRIZIA

GIANNATEMPO, PATRIZIA  

Universita' degli Studi di MILANO  

Risultati 1 - 15 di 15 (tempo di esecuzione: 0.156 secondi).
Titolo Data di pubblicazione Autore(i) Tipo File Abstract
Biomarker-driven immunotherapy for precision medicine in prostate cancer 1-gen-2022 Ottini A.Sepe P.Beninato T.Verzoni E.Giannatempo P.De Braud F.Procopio G. + Article (author) -
Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma 1-giu-2015 E. VerzoniA. NecchiP. GiannatempoD. RaggiF. De Braud + Article (author) -
Corrigendum to “Recommendations for surveillance and follow-up of men with testicular germ cell tumors: A multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica” (Critical Reviews in Oncology / Hematology (2019) 137 (154–164), (S1040842819300587), (10.1016/j.critrevonc.2019.03.006)) 1-feb-2020 Barone D.Cai T.Carrafiello G.Giannatempo P.Marchiano' A.Palazzi S.Procopio G.Secondino S.Valcamonico F.De Giorgi U. + Article (author) -
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy 1-apr-2015 A. NecchiP. GiannatempoE. FarèD. RaggiF. De Braud + Article (author) -
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer 1-giu-2014 A. NecchiP. GiannatempoD. RaggiE. FarèF.G. De Braud + Article (author) -
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes 1-nov-2013 A. NecchiD. RaggiE. FarèP. GiannatempoA.M. Gianni + Article (author) -
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma 1-feb-2016 P. PinciroliP. GiannatempoD. RaggiF.G. De BraudA. Necchi + Article (author) -
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer 1-apr-2016 A. NecchiD. RaggiP. GiannatempoG. PelosiF.G. De Braud + Article (author) -
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial 1-gen-2012 A. NecchiP. GiannatempoM. PennatiF. De BraudA.M. Gianni + Article (author) -
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment 1-nov-2013 P. GiannatempoD. RaggiE. FaréD. BiasoniA.M. GianniA. Necchi + Article (author) -
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer : an open label, single-group, phase 2 trial 1-giu-2014 A. NecchiP. GiannatempoE. FarèD. RaggiPENNATI, MARZIAE. TogliardiF. De Braud + Article (author) -
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation 1-lug-2015 D. RaggiP. GiannatempoE. VerzoniF. De BraudA. Necchi + Article (author) -
Quality of life and pain control following laparoscopic retroperitoneal lymph node dissection in early-stage nonseminoma. 1-mag-2015 E. BianchiC. L’AcquaD. RaggiP. GiannatempoE. FaréM. Langer + Article (author) -
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma : a systematic review and meta-analysis of patient outcomes 1-apr-2015 P. GiannatempoE. FarèD. RaggiB. AvuzziF. De BraudA. Necchi + Article (author) -
Recommendations for surveillance and follow-up of men with testicular germ cell tumors: a multidisciplinary consensus conference by the Italian Germ cell cancer Group and the Associazione Italiana di Oncologia Medica 1-gen-2019 Barone D.Cai T.Carrafiello G.Giannatempo P.Marchiano' A.Palazzi S.Procopio G.Secondino S.Valcamonico F.De Giorgi U. + Article (author) -